Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM49RI7)

Drug Name

EP-51216 Drug Info

Synonyms

(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-(4-aminobutanoylamino)-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]hexanamide

Indication

Disease Entry	ICD 11	Status	REF
Eating disorder	6B82	Phase 1	[1]

Cross-matching ID

PubChem CID: 6918424
TTD Drug ID: DM49RI7

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Growth hormone receptor (GHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pegvisomant	DMDEZI3	Acromegaly	5A60.0	Approved	[2]
Somatropin recombinant	DMF3GM2	Fetal growth restriction	KA20.1Z	Approved	[3]
SKF-110679	DMNRHMX	Growth hormone deficiency	5A61.3	Phase 2	[4]
PH-794428	DM71HVW	Growth hormone deficiency	5A61.3	Phase 2	[5]
IONIS-GHR-LRx	DMQ9711	Acromegaly	5A60.0	Phase 2	[6]
Syntropin	DMH76KD	Dwarfism	5B11	Phase 1	[7]
EP-51389	DMW739O	Eating disorder	6B82	Phase 1	[1]
AOD-9604	DMGDPSI	Obesity	5B81	Discontinued in Phase 2	[8]
BVT-A	DMDSX58	Acromegaly	5A60.0	Preclinical	[9]
NNC-26-0194	DMDCPFJ	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth hormone receptor (GHR)	TTKMAZ6	GHR_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
2	Growth hormone receptor antagonist treatment reduces exercise performance in young males. J Clin Endocrinol Metab. 2009 Sep;94(9):3265-72.
3	Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006 Feb;22(2):351-7.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1093).
5	PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans.Xenobiotica.2008 Oct;38(10):1340-51.
6	ClinicalTrials.gov (NCT04522180) An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherapy in Patients With Acromegaly. U.S.National Institutes of Health.
7	Late feedback effects of hypothalamic-pituitary-adrenal axis hormones in healthy subjects. Psychoneuroendocrinology. 1998 May;23(4):371-83.
8	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
9	Emerging drugs for acromegaly. Expert Opin Emerg Drugs. 2008 Jun;13(2):273-93.
10	Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998 Nov;28(11):1083-92.